Seasonal Influenza
44
1
1
42
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
15 trials with published results (34%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.3%
1 terminated out of 44 trials
97.7%
+11.2% vs benchmark
50%
22 trials in Phase 3/4
36%
15 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 42 completed trials
Clinical Trials (44)
A Study of Modified mRNA Vaccines in Healthy Adults
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Yearly Strain Variation Study, 2010/2011